Search results for: Multi-Indication Medicines
Filter search results
Value Based Pricing in Sweden: Lessons for Design?
28 November 2012
…which is the health technology assessment (HTA) agency in Sweden. In Sweden, the TLV makes decisions on the reimbursement status of new medicines, under a system introduced in 2002. Its…
OHE at HTAi Oslo: A New Drug Development Paradigm, a Framework for Developing Formularies in MICs, and the Effect of NICE Decisions Abroad
15 June 2015
…companies, which set out development pathways for different drug ‘archetypes’ and (ii) initial findings from the Innovative Medicines Initiative (IMI) ‘GetReal’ Project proposing innovative (more pragmatic) trial designs in pre-and…
OHE at HTAi Oslo: A New Drug Development Paradigm, and the Effect of NICE Decisions Abroad
19 June 2015
…out development pathways for different drug ‘archetypes’ and (ii) initial findings from the Innovative Medicines Initiative (IMI) ‘GetReal’ Project proposing innovative (more pragmatic) trial designs in pre-and post-launch drug development….
Presentations and Posters from ISPOR Europe 2016
24 November 2016
…the conference. This post contains their presentations and posters. Plenary session: Differential Pricing of Medicines in Europe: Implications for Access, Innovation, and Affordability. Moderator: Lou Garrison (University of Washington and OHE)….
The challenges and economics of drug development in 2022
1 July 2013
…gene-based treatments or medicines paired with diagnostics. For payers, the more targeted treatments require new approaches to HTA and pricing, even pricing by indication in some cases. For policy makers,…
Finance of Medical Research
7 January 1964
…premature death. The discovery of new medicines and the development of new medical… The explosive progress of medical science during the past twenty-five years has brought about a revolution in…
Factors Which May Affect Expenditure on Health
1 July 1965
…was formerly no treatment may now respond to newly discovered medicines or newly developed surgical techniques. Ill health which was previously ignored may now be brought for treatment; the existence…
Delivering the Triple Win: A Value-Based Approach to Pricing
20 April 2023
…access medicines in a way that is sustainable for healthcare systems whilst also supporting a sustainable stream of innovation that delivers continuous improvements in the treatment options available for patients….
Are Cost-Effectiveness Thresholds Fit for Purpose for Real-World Decision Making on Access to and Pricing of Pharmaceuticals? A New OHE Paper on Current Methods and Practices, and a Novel Approach for Optimal Thresholds
3 March 2020
…Institute for Health and Care Excellence (NICE) in the UK) – or implicitly – where a threshold is informally accepted by decision makers (e.g. Canada – before the Patented Medicines…